These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 2287059

  • 1. [Susceptibility of clinically isolated bacterial strains to imipenem/cilastatin sodium].
    Daimon Y.
    Jpn J Antibiot; 1990 Nov; 43(11):1948-55. PubMed ID: 2287059
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Clinical laboratory approach to estimating the effective administration dose of imipenem/cilastatin. Evaluation of the disk susceptibility test and its interpretation system].
    Matsuo K, Uete T.
    Jpn J Antibiot; 1989 Nov; 42(11):2377-92. PubMed ID: 2621780
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Susceptibilities of clinical bacterial isolates to antimicrobial agents. A study mainly focused on imipenem. Research Group for Testing Imipenem Susceptibility on Clinical Isolates].
    Igari J.
    Jpn J Antibiot; 1990 Oct; 43(10):1723-82. PubMed ID: 2086814
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
    Igari J, Oguri T, Hiramatsu N, Akiyama K, Koyama T.
    Jpn J Antibiot; 2003 Oct; 56(5):458-96. PubMed ID: 14692381
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
    Igari J, Oguri T, Hiramatsu N, Akiyama K, Koyama T.
    Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920
    [Abstract] [Full Text] [Related]

  • 13. [Susceptibility of clinically isolated strains to aztreonam].
    Daimon Y.
    Jpn J Antibiot; 1988 Nov; 41(11):1623-34. PubMed ID: 3145344
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Antibacterial activities of monobactams against fresh clinical isolates].
    Deguchi K, Yokota N, Koguchi M, Nakane Y, Fukayama S, Nishimura Y, Oda S, Tanaka S, Kato M, Sato K.
    Jpn J Antibiot; 1988 Nov; 41(11):1600-22. PubMed ID: 3210297
    [Abstract] [Full Text] [Related]

  • 20. [Susceptibility of clinical isolates to aztreonam].
    Nagasawa Z, Nishimura T, Nagumo F, Ueda H, Tadano J, Katoh O, Yamada H.
    Jpn J Antibiot; 1989 Jun; 42(6):1257-70. PubMed ID: 2507799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.